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INTRODUCTION 
 Discoid lupus erythematosus (DLE) is a chronic, indolent, disfiguring disease that is characterized by scaly, erythematous, disk-
shaped patches and plaques followed by atrophy, scarring and depigmentation.  
 In a small number of patients, it is refractory to standard therapies.  
 In those cases, thalidomide has been reported to be an effective treatment. 
 Its anti-inflammatory and immunomodulatory actions are thought to contribute to its efficacy in DLE.  
 The most fearful side effects are teratogenicity and sensory peripheral neuropathy.  
 Adequate counseling and vigilance must be given to the patients. 
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 A 45-year-old healthy Caucasian woman presented 
with a 20-year history of severe facial and scalp DLE 
confirmed by histopathology. 
 The lesions failed to respond to previous therapies: 
 Corticosteroids (topical, intralesional, oral), 
 Hydroxychloroquine, 
 Methotrexate, 
 Azathioprine, 
 Topical tacrolimus. 
 5 criteria for Systemic Lupus Erythematosus were 
fulfilled: 
 DLE, 
 Photosensitivity, 
 Oral ulcers, 
 Non-erosive arthritis,  
 Positive antinuclear antibody. 
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Figure 1. (A-C) Multiple  facial well-demarcated, scaly erythematous 
plaques. (D) Involvement of the scalp has led to alopecia with 
erythema, atrophy and adherent scale. 
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Thalidomide was initiated at a dosage of 50mg/day and the skin lesions had improved dramatically after three weeks. 
Two months later, the dose was reduced to 50mg, five days per week without disease rebound. 
Complete clinical remission was observed after eight months of treatment. 
 The other concomitant medications during the treatment included sunscreen, hydroxycholoroquine, enoxaparin and aspirin to 
prevent thromboembolic events.  
 Thalidomide also allowed the reduction of oral corticosteroids (deflazacort 30mg/day to 6mg/day), without clinical worsening. 
 Pregnancy testing, routine laboratory and electrocardiography were performed at regular intervals for safety monitoring and 
the results were within normal limits.  
 An effective contraceptive method (intrauterine device) was guaranteed. 
 Only minor side effects as nausea, constipation and somnolence were noted, however, they improved with dose reduction.  
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3 weeks after treatment with thalidomide 50 mg/day. Complete clinical remission after 8 months 
with thalidomide 50 mg/5 days per week. 
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DISCUSSION 
Our data confirm that thalidomide therapy is an alternative or adjunctive treatment for patients with severe and chronic DLE that 
is refractory to standard therapies. 
CONCLUSION 
 Approximately 25% of DLE lesions fail to respond to standard first-line systemic therapy with antimalarial agents. 
 Among the alternative systemic therapies, thalidomide is an accepted treatment and has demonstrated clinical efficacy in up to 
90% of recalcitrant cases in some studies. 
 Doses as low as 50 mg daily were frequently effective in keeping clinical remission. 
 In this patient, low-dose thalidomide was an effective treatment with minimal side effects. 
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